{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:06:19Z","timestamp":1786975579706,"version":"build-2736575974"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"\n Importance<\/jats:title>\n Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To explore the potential for valsartan to modify disease development, and to characterize short-term phenotypic progression in subclinical HCM.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) randomized clinical trial was conducted from April 2014 to July 2019 at 17 sites in 4 countries (Brazil, Canada, Denmark, and the US), with 2 years of follow-up. The prespecified exploratory VANISH cohort studied here included sarcomere variant carriers with subclinical HCM and early phenotypic manifestations (reduced E\u2032 velocity, electrocardiographic abnormalities, or an increased left ventricular [LV] wall thickness [LVWT] to cavity diameter ratio) but no LV hypertrophy (LVH). Data were analyzed between March and December 2022.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Treatment with placebo or valsartan (80 mg\/d for children weighing &amp;lt;35 kg, 160 mg\/d for children weighing \u226535 kg, or 320 mg\/d for adults aged \u226518 years).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary outcome was a composite\n z<\/jats:italic>\n score incorporating changes in 9 parameters of cardiac remodeling (LV cavity volume, LVWT, and LV mass; left atrial [LA] volume; E\u2032 velocity and S\u2032 velocity; and serum troponin and N-terminal prohormone of brain natriuretic peptide levels).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n This study included 34 participants, with a mean (SD) age of 16\u2009(5) years (all were White). A total of 18 participants (8 female [44%] and 10 male [56%]) were randomized to valsartan and 16 (9 female [56%] and 7 male [44%]) were randomized to placebo. No statistically significant effects of valsartan on cardiac remodeling were detected (mean change in composite\n z<\/jats:italic>\n score compared with placebo: \u22120.01 [95% CI, \u22120.29 to 0.26];\n P<\/jats:italic>\n \u2009=\u2009.92). Overall, 2-year phenotypic progression was modest, with only a mild increase in LA volume detected (increased by 3.5 mL\/m\n 2<\/jats:sup>\n [95% CI, 1.4-6.0 mL\/m\n 2<\/jats:sup>\n ];\n P<\/jats:italic>\n \u2009=\u2009.002). Nine participants (26%) had increased LVWT, including 6 (18%) who developed clinically overt HCM. Baseline LA volume index (LAVI; 35 vs 28 mL\/m\n 2<\/jats:sup>\n ;\n P<\/jats:italic>\n \u2009=\u2009.01) and average interventricular septum thickness (8.5 vs 7.0 mm;\n P<\/jats:italic>\n \u2009=\u2009.009) were higher in participants who developed HCM.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this exploratory cohort, valsartan was not proven to slow progression of subclinical HCM. Minimal changes in markers of cardiac remodeling were observed, although nearly one-fifth of patients developed clinically overt HCM. Transition to disease was associated with greater baseline interventricular septum thickness and LAVI. These findings highlight the importance of following sarcomere variant carriers longitudinally and the critical need to improve understanding of factors that drive disease penetrance and progression.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT01912534<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2023.2808","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T11:02:58Z","timestamp":1693998178000},"page":"1083","source":"Crossref","is-referenced-by-count":26,"title":["Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy"],"prefix":"10.1001","volume":"8","author":[{"given":"Christoffer Rasmus","family":"Vissing","sequence":"first","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Axelsson Raja","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene M.","family":"Day","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Russell","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Zahka","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry M.","family":"Lever","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre C.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Laboratory of Genetics and Molecular Cardiology, Heart Institute, University of S\u00e3o Paulo Medical School, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Colan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Margossian","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Canter","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Bach","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Rossano","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali T.","family":"Owens","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Benson","sequence":"additional","affiliation":[{"name":"Toronto Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Mestroni","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R. G.","family":"Taylor","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Wilmot","sequence":"additional","affiliation":[{"name":"Heart Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Thrush","sequence":"additional","affiliation":[{"name":"Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Soslow","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Becker","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Pittsburgh School of Medicine and UPMC, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Seidman","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Howard Hughes Medical Institute, Chevy Chase, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K.","family":"Lakdawala","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Cirino","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum A.","family":"MacRae","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bundgaard","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. John","family":"Orav","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Ho","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose E","family":"Krieger","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Sacilotto","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmundo","family":"Arteaga","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murilo O.","family":"Antunes","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euan","family":"Ashley","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly Y.","family":"Lin","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Kevin","family":"Hall","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Choudhury","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfriede","family":"Pahl","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose D.","family":"Vargas","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Lewis","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"hbr230018r1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"hbr230018r2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1161\/CIRCULATIONAHA.114.013478","article-title":"Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons.","volume":"132","author":"Ranthe","year":"2015","journal-title":"Circulation"},{"issue":"10","key":"hbr230018r3","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"hbr230018r4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ahj.2017.02.008","article-title":"The design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial.","volume":"187","author":"Ho","year":"2017","journal-title":"Am Heart J"},{"issue":"12","key":"hbr230018r5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006231","article-title":"Baseline characteristics of the VANISH cohort.","volume":"12","author":"Axelsson Raja","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"22","key":"hbr230018r6","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1136\/heartjnl-2016-310015","article-title":"Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers.","volume":"102","author":"Ho","year":"2016","journal-title":"Heart"},{"issue":"8","key":"hbr230018r7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.117.032966","article-title":"Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy.","volume":"138","author":"Axelsson Raja","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"hbr230018r8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jacc.2021.07.017","article-title":"Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy.","volume":"78","author":"de Marvao","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hbr230018r9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ahj.2004.07.017","article-title":"Left atrial volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy.","volume":"149","author":"Sachdev","year":"2005","journal-title":"Am Heart J"},{"issue":"10","key":"hbr230018r10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.echo.2005.06.011","article-title":"Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity.","volume":"18","author":"Yang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"hbr230018r11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/heartjnl-2016-309672","article-title":"Predictors of atrial fibrillation in hypertrophic cardiomyopathy.","volume":"103","author":"Guttmann","year":"2017","journal-title":"Heart"},{"issue":"1","key":"hbr230018r12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.111.090514","article-title":"Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing.","volume":"127","author":"Jensen","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"hbr230018r13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jacc.2020.06.011","article-title":"Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers.","volume":"76","author":"Lorenzini","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"hbr230018r14","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/eurheartj\/ehp306","article-title":"Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers.","volume":"30","author":"Michels","year":"2009","journal-title":"Eur Heart J"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2809258\/jamacardiology_vissing_2023_br_230018_1698258734.98643.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T11:06:42Z","timestamp":1699441602000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2809258"}},"subtitle":["The VANISH Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.2808","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}